Fuller & Thaler Asset Management, Inc. Exelixis, Inc. Transaction History
Fuller & Thaler Asset Management, Inc.
- $27 Billion
- Q2 2025
A detailed history of Fuller & Thaler Asset Management, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Fuller & Thaler Asset Management, Inc. holds 8,775,572 shares of EXEL stock, worth $331 Million. This represents 1.43% of its overall portfolio holdings.
Number of Shares
8,775,572
Previous 7,795,074
12.58%
Holding current value
$331 Million
Previous $288 Million
34.41%
% of portfolio
1.43%
Previous 1.13%
Shares
26 transactions
Others Institutions Holding EXEL
# of Institutions
688Shares Held
260MCall Options Held
1.41MPut Options Held
1.55M-
Black Rock Inc. New York, NY33.5MShares$1.26 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA27.5MShares$1.04 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA16MShares$604 Million3.18% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.8MShares$596 Million0.99% of portfolio
-
State Street Corp Boston, MA11.4MShares$429 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $12.1B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...